Türkmen Ilknur Çetinaslan, Başsüllü Nuray, Korkmaz Pınar, Günenç Banu, Baykal Cem Murat, Güdücü Nilgün, Işçı Herman, Dünder Ilkkan, Doğusoy Gülen Bülbül
Department of Pathology, İstanbul Bilim University Faculty of Medicine, İSTANBUL, TURKEY.
Turk Patoloji Derg. 2013;29(3):179-84. doi: 10.5146/tjpath.2013.01182.
Cervical carcinoma has been included in the preventable diseases category ever since the use of cervical cytology in routine practice. The Pap test is an efficient screening test. We aimed to compare the cervical cytology diagnosis with biopsy and smear follow up results in our institution.
We aimed to compare the diagnosis of cytology material examined in our institution during the 2009-2012 period with their biopsy and smear follow ups. The diagnoses were compared with the follow up smears and/or cervical biopsies.
13610 Pap tests were examined during September 2009-July 2012. Among these cases, there were 370 atypical squamous cells of undetermined significance (ASCUS), 29 atypical squamous cells-high grade intraepithelial lesions cannot be excluded (ASC-H), 155 low grade squamous intraepithelial lesion (LSIL), 33 high grade squamous intraepithelial lesion (HSIL), and 5 atypical glandular cell (AGC) diagnoses. The ratio of atypical squamous cell (ASCUS and ASC-H) to squamous intraepithelial lesions was 2.12. Squamous intraepithelial lesion was verified in 47 of 91 ASCUS cases. Among patients who had a cervical biopsy, 52 of 64 LSIL cases and all of the 21 HSIL cases had biopsy-proven SIL.
Atypical squamous cell (ASC) is the most common diagnosis in abnormal cervical cytology. As it is indefinite, ASC is used as a quality assurance parameter and the aim is to decrease its use. As the ratio of epithelial cell abnormality is variable in different populations, the ASC/SIL is a more definite variable to be used for quality assurance. The efficiency in clinical use of the cervical cytology screening test is determined by biopsy verification. Our epithelial cell abnormality, ASC/SIL ratio and cytology-histology correlation values were parallel to the literature, proving that the methods are used reliably at our institution.
自从在常规实践中使用宫颈细胞学检查以来，宫颈癌已被列入可预防疾病类别。巴氏试验是一种有效的筛查试验。我们旨在比较本院宫颈细胞学诊断结果与活检及涂片随访结果。
我们旨在比较2009年至2012年期间本院检查的细胞学材料诊断结果与其活检及涂片随访情况。将诊断结果与随访涂片和/或宫颈活检结果进行比较。
2009年9月至2012年7月期间共检查了13610例巴氏试验。在这些病例中，有370例意义不明确的非典型鳞状细胞（ASCUS）、29例不能排除高级别上皮内病变的非典型鳞状细胞（ASC-H）、155例低级别鳞状上皮内病变（LSIL）、33例高级别鳞状上皮内病变（HSIL）以及5例非典型腺细胞（AGC）诊断。非典型鳞状细胞（ASCUS和ASC-H）与鳞状上皮内病变的比例为2.12。91例ASCUS病例中有47例确诊为鳞状上皮内病变。在接受宫颈活检的患者中，64例LSIL病例中有52例以及所有21例HSIL病例经活检证实为鳞状上皮内病变（SIL）。
非典型鳞状细胞（ASC）是宫颈细胞学异常中最常见的诊断。由于其不确定性，ASC被用作质量保证参数，目标是减少其使用。由于不同人群中上皮细胞异常的比例各不相同，ASC/SIL是用于质量保证的更明确变量。宫颈细胞学筛查试验的临床应用效率由活检验证确定。我们的上皮细胞异常、ASC/SIL比例以及细胞学与组织学的相关性值与文献一致，证明这些方法在本院得到了可靠应用。
